Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis

Psoriasis is the first disease to have been successfully treated with therapeutics that directly block the action of the cytokines of the IL-23 and IL-17 pathway. Furthermore, inhibitors of IL-23 and IL-17 intracellular signalling are in clinical development.

Source:

The Lancet